Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung

7680676170011 CH-67617 Injektionslösung zur subkutanen Anwendung
Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Injektionslösung zur subkutanen Anwendung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
25/09/2025
Patient information leaflet
Français
25/09/2025
Patient information leaflet
Italien
25/09/2025
Summary of Product Characteristics
Allemand
25/09/2025
Summary of Product Characteristics
Français
25/09/2025
Summary of Product Characteristics
Italien
25/09/2025

Detailed composition

Substance Quantity Type Category
(N/A)
120.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 7164.10
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/04/2022

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
67617
Drug name
Enspryng, Injektionslösung zur subkutanen Anwendung
Galenic form
INLFS
ATC Code
L04AC19
Authorization status
Z
Dispensing category
A
First authorization
13/07/2020
Authorization expiration date
31/12/9999
IT Number
07.15.0.
Domain
Human medicine
Field of application
Behandlung von Erwachsenen und Jugendlichen mit Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD)

Package details

Description (FR)
ENSPRYNG sol inj 120 mg/ml ser pré 1 ml
Description (DE)
ENSPRYNG Inj Lös 120 mg/ml Fertspr 1 ml
Market launch
13/07/2020
Narcotic (BTM)
No